Surio Therapeutics

Surio Therapeutics is a biotechnology company focused on developing next-generation gene therapy delivery vehicles. Utilizing a platform based on directed evolution, the company engineers Adeno-associated virus (AAV) capsids to overcome existing challenges such as pre-existing immunity and poor tissue specificity. Their technology aims to enable more effective and safer gene therapies for a variety of genetic and acquired diseases. The company was co-founded by pioneers in the field of viral vector engineering from leading academic institutions like UC Berkeley. Surio is currently in the pre-clinical stage, advancing a pipeline of optimized vectors for diverse therapeutic applications.